Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

c-TRAK TN: ctDNA surveillance to trigger pembrolizumab in early triple-negative breast cancer

Phase 2 trial that uses serial ctDNA to detect residual disease after primary treatment for moderate- or high-risk early triple-negative breast cancer and to start pembrolizumab. ClinicalTrials.gov lists the status as unknown.

Institute of Cancer Research, United Kingdom